Shots:
- In the P-I SPICE study, the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing regimen in late-stage cancer patients to treat a range of tumor types
- PsiOxus will be responsible to conduct P-I study with patient recruitment expected to initiate in Q3’21
- NG-641 is a tumor re-engineering product using PsiOxus’ T-SIGn platform based upon the enadenotucirev vector while Opdivo is a PD-1 immune checkpoint inhibitor, designed to harness the body’s own immune system to help restore anti-tumor immune response
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration first appeared on PharmaShots.
